Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12623001068651
Ethics application status
Approved
Date submitted
18/09/2023
Date registered
5/10/2023
Date last updated
6/06/2024
Date data sharing statement initially provided
5/10/2023
Type of registration
Prospectively registered
Titles & IDs
Public title
Positioning of Esketamine Treatment (PoET) in the real-world management of depression
Query!
Scientific title
Evaluating the Positioning of Esketamine Treatment (PoET) for symptom management in adults with major depressive disorder
Query!
Secondary ID [1]
309907
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
PoET
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Major Depressive Disorder
331214
0
Query!
Condition category
Condition code
Mental Health
327979
327979
0
0
Query!
Depression
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
This is an uncontrolled, single arm, naturalistic study. There will be three treatment phases: Phase 1 - Acute treatment phase (weeks 1-4); Phase 2 - Maintenance treatment phase (weeks 5-8); Phase 3 - Continuation treatment phase (Weeks 9-25). Phase 1 is the critical component of our study as it determines our primary outcomes.
Name of drug: esketamine
Dose: initial first dose is 56mg; subsequent doses will be 56mg or 84mg
Duration: twice weekly for weeks 1-4; once weekly for weeks (5-8); once weekly/once fortnightly/once monthly as clinically indicated for weeks (9-25). After each treatment phase, participants will be re-assessed through a comprehensive battery of assessments and dose adjustments will be performed by the study psychiatrist based on tolerability, treatment response, and ongoing consent.
Mode of administration: intranasal spray; self-administration with direct supervision
Adherence to intervention: The intervention is dispensed and provided within the CADE clinic; therefore, participants' attendance at the clinic is required
Query!
Intervention code [1]
326835
0
Treatment: Drugs
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
335845
0
Percentage of treatment responders determined by a 50% reduction on the Hamilton Depression Rating Scale (HAM-D) 17-Item scoring.
Query!
Assessment method [1]
335845
0
Query!
Timepoint [1]
335845
0
At the conclusion of the study
Query!
Primary outcome [2]
336083
0
Mean depression score on the Quick Inventory of Depressive Symptomatology Self-report (QIDS-SR) 16-Item.
Query!
Assessment method [2]
336083
0
Query!
Timepoint [2]
336083
0
Baseline, after first treatment, at the end of weeks 1,2,3, and 4 (primary time point); and further after week 8 and week 12 after Esketamine was commenced.
Query!
Primary outcome [3]
336084
0
Global functioning determined by Clinical Global Impression (CGI) score.
Query!
Assessment method [3]
336084
0
Query!
Timepoint [3]
336084
0
Baseline, week 1, week 2, week 3, week 4 (primary time point), week 8 and week 12 after Esketamine was commenced.
Query!
Secondary outcome [1]
425868
0
Change in mood symptom scores assessed using the visual analogue scale (self-reported).
Query!
Assessment method [1]
425868
0
Query!
Timepoint [1]
425868
0
Baseline and following each administration of Esketamine until this is ceased.
Query!
Secondary outcome [2]
426783
0
Depressive symptoms assessed using the Beck Depression Inventory (BDI) 21-Item.
Query!
Assessment method [2]
426783
0
Query!
Timepoint [2]
426783
0
Baseline and at week 4 after Esketamine was commenced.
Query!
Secondary outcome [3]
426784
0
Anxiety symptoms assessed using the State-Trait Anxiety Inventory (STAI)
Query!
Assessment method [3]
426784
0
Query!
Timepoint [3]
426784
0
Baseline and at week 4 after Esketamine was commenced.
Query!
Eligibility
Key inclusion criteria
1. Be an adult aged 18-65 years old
2. Have a primary diagnosis of Major Depressive Disorder (MDD)
***Please note: a co-morbid diagnosis of an anxiety disorder or ADHD can be included***
3. Be currently depressed and on medication for current episode
4. Have experienced an inadequate response to 2 or more courses of antidepressants (of adequate dose and duration)
5. Be maintained on their current antidepressant medication or psychological therapy at the time of enrolment
6. Able to understand and able to provide informed consent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Concurrent diagnoses
- Participants with DSM-5 disorders e.g., current substance misuse disorder, bipolar disorder, schizophrenia
- Participants who are unable to understand the study and therefore unable to provide informed consent
2. Pregnancy
- Participants who are pregnant and/or breastfeeding
- Participants who are not willing to avoid pregnancy for themselves or their partners during the study by using effective birth control methods
3. Current medications
- Participants taking a total daily dose of benzodiazepines greater than the equivalent of 6mg/day of lorazepam
- Participants on complementary and alternative medicine therapies i.e., St John’s wort, Chinese medicines, and various herbal and homeopathic treatments
4. Stimulants
- Participants taking stimulants such as methylphenidate, amphetamine, and dextroamphetamine for a diagnosis such as ADHD can still have Esketamine provided they do not continue taking stimulants concurrently for the duration of the study.
- Concurrent use is excluded due to the synergistic effect with Esketamine that can cause increased blood pressure.
5. Medical history
- Participants with current or past history of seizures (uncomplicated childhood febrile seizures with no sequelae are not exclusionary)
- Participants with a history of uncontrolled hypertension
- Participants with uncontrolled diabetes mellitus
- Participants with aneurysmal vascular disease including thoracic and abdominal aorta, intracranial and peripheral arterial vessels, or arteriovenous malformation, intracerebral haemorrhage
- Participants with untreated glaucoma, current penetrating or perforating eye injury, brain injury, hypertensive encephalopathy, intrathecal therapy with ventricular shunts, or any other condition associated with increased intracranial pressure or increased intraocular pressure or planned eye surgery
- Participants who are currently receiving electroconvulsive therapy (ECT) or have received ECT in the past month
6. Substance Misuse History
- Participants who have ever had a substance misuse disorder involving any of the following over their lifetime: ketamine, phencyclidine (PCP), lysergic acid diethylamide (LSD), or 3,4-methylenedioxy-methamhetamine (MDMA), or other hallucinogen use history
- Participants with hypersensitivity to Esketamine, Ketamine, or any of the excipients
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
17/10/2023
Query!
Actual
31/10/2023
Query!
Date of last participant enrolment
Anticipated
24/03/2025
Query!
Actual
Query!
Date of last data collection
Anticipated
15/09/2025
Query!
Actual
Query!
Sample size
Target
162
Query!
Accrual to date
11
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
25436
0
Royal North Shore Hospital - St Leonards
Query!
Recruitment postcode(s) [1]
41178
0
2065 - St Leonards
Query!
Funding & Sponsors
Funding source category [1]
314089
0
Commercial sector/Industry
Query!
Name [1]
314089
0
Janssen-Cilag Pty Ltd
Query!
Address [1]
314089
0
66 Waterloo RdMacquarie Park NSW 2113
Query!
Country [1]
314089
0
Australia
Query!
Primary sponsor type
Government body
Query!
Name
Northern Sydney Local Health District
Query!
Address
Level 14, Kolling Building 10 Westbourne Ave St Leonards NSW 2065
Query!
Country
Australia
Query!
Secondary sponsor category [1]
316002
0
None
Query!
Name [1]
316002
0
Query!
Address [1]
316002
0
Query!
Country [1]
316002
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
313226
0
Northern Sydney Local Health District Human Research Ethics Committee
Query!
Ethics committee address [1]
313226
0
Level 13, Kolling BuildingRoyal North Shore Hospital Reserve Road, St Leonards NSW 2065
Query!
Ethics committee country [1]
313226
0
Australia
Query!
Date submitted for ethics approval [1]
313226
0
23/06/2023
Query!
Approval date [1]
313226
0
01/08/2023
Query!
Ethics approval number [1]
313226
0
2023/ETH01392
Query!
Summary
Brief summary
Depression is a common mental illness, and it is one of the leading causes of disease burden worldwide. Fortunately, there are many effective treatments available for depression, including lifestyle changes, psychological treatments, and medications such as antidepressants. However, not all patients will respond to the first treatment prescribed. Some patients may only experience a 'partial response', where a few treatments help their depression somewhat, but they do not achieve a full recovery. Currently, the reasons why some patients do not respond, or only experience a partial response to an antidepressant, is not fully understood.
Recently, researchers have been investigating new medications that may help patients recover from depression. One of these new medications is Esketamine, which is a relatively new molecule derived from a drug called Ketamine - an anaesthetic that has been used medically for decades. Researchers have been investigating the antidepressant properties of Ketamine for a long time. It is thought that Ketamine, and its derivative, Esketamine, help to treat depression for a number of reasons. However, it is not yet known which patients benefit most from Esketamine when used in conjunction with conventional antidepressants. In addition, we do not yet understand how the effect of Esketamine is impacted by other treatments that a patient may be taking for their depression. Finally, it has not yet been investigated how patients with a partial response to an antidepressant will benefit from adding Esketamine to their therapeutic regimen without switching to a new baseline antidepressant. Therefore, there are two principle aims of this study 1) to investigate whether Esketamine is effective when added to ongoing antidepressant treatment and 2) to identify patient characteristics that will determine a therapeutic response to Esketamine in real-world practice.
In patients that improve with the addition of Esketamine to their current antidepressant treatment, we hypothesize that their improvement will be determined by their personal characteristics and/or the type of treatment they are already receiving.
Query!
Trial website
https://www.cadeclinic.com/poetstudy
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
127414
0
Prof Gin Malhi
Query!
Address
127414
0
CADE (Clinical Assessment and Diagnostic Evaluation) Clinic, Level 3, Royal North Shore Hospital, Reserve Road, St Leonards, NSW 2065
Query!
Country
127414
0
Australia
Query!
Phone
127414
0
+61 2 9462 9909
Query!
Fax
127414
0
Query!
Email
127414
0
[email protected]
Query!
Contact person for public queries
Name
127415
0
Miss Erica Bell
Query!
Address
127415
0
CADE (Clinical Assessment and Diagnostic Evaluation) Clinic, Level 3, Royal North Shore Hospital, Reserve Road, St Leonards, NSW 2065
Query!
Country
127415
0
Australia
Query!
Phone
127415
0
+61 294639905
Query!
Fax
127415
0
Query!
Email
127415
0
[email protected]
Query!
Contact person for scientific queries
Name
127416
0
Miss Erica Bell
Query!
Address
127416
0
CADE (Clinical Assessment and Diagnostic Evaluation) Clinic, Level 3, Royal North Shore Hospital, Reserve Road, St Leonards, NSW 2065
Query!
Country
127416
0
Australia
Query!
Phone
127416
0
+61 294639905
Query!
Fax
127416
0
Query!
Email
127416
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Doc. No.
Type
Citation
Link
Email
Other Details
Attachment
20099
Ethical approval
386089-(Uploaded-23-08-2023-10-33-40)-Study-related document.pdf
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF